Urs Duthaler
Clinical Pharmacologist and Researcher
Data updated
Research Footprint
Urs Duthaler appears in 14 tracked papers (2019–2024), most studied alongside LSD, Psilocybin and MDMA, across Healthy Volunteers, Medicinal Chemistry & Drug Development and Anxiety Disorders.
Most-cited paper: Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects (238 citations).
Frequent co-authors: Matthias Liechti, Friederike Holze and Nikhil Varghese.
Background & Research
Urs Duthaler is a clinical pharmacologist and researcher who has played a central role in contemporary human experimental studies of classic serotonergic psychedelics. Working frequently in collaboration with Matthias E. Liechti and other Swiss research groups, he has contributed to a series of randomized, double-blind, placebo-controlled cross-over trials in healthy volunteers examining acute, dose-dependent effects of LSD, intravenous DMT, co‑administration of MDMA and LSD, and head‑to‑head comparisons of mescaline, LSD and psilocybin. These studies emphasise careful pharmacological characterisation, robust blinding and standardised psychometric and physiological assessments, informing both basic neuropharmacology and clinical translational efforts.
Key Impact
Noted for advancing human experimental psychedelic research through rigorous, placebo-controlled studies and investigations into the pharmacokinetics and metabolism of classic serotonergic psychedelics.
Collaboration Network
25 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Urs Duthaler is associated with.